オプションチェーンは、Envoy Medicalの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Envoy Medicalの市場センチメントを評価します。.

Envoy Medical (NASDAQ:COCH) 株価情報, オプションチェーン

Envoy Medical

Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.

Envoy Medical, Inc. - Class A Common Stock

Envoy Medical Inc

Cochlear Ltd

UBS analyst Pradeep Ramani maintains ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Neutral and lowers the price target from $55 to $40.

News

Price Target

Analyst Ratings

UBS Maintains Neutral on ON Semiconductor, Lowers Price Target to $40

WIIM

Wells Fargo shares are trading higher after the company's board authorized a $40 billion stock repurchase program.

UBS analyst Kunal Madhukar maintains Match Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) with a Neutral and lowers the price target from $34 to $31.

MTCH

UBS Maintains Neutral on Match Group, Lowers Price Target to $31

Correction: Guggenheim analyst Michael Schmidt downgrades SpringWorks Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) from Buy to Neutral and lowers the price target from $77 to $47. (Analyst Firm change from Stephens &amp; Co. to Guggenheim)

Downgrades

SWTX

Correction: Guggenheim Downgrades SpringWorks Therapeutics to Neutral, Lowers Price Target to $47 (Firm change from Stephens & Co. to Guggenheim)

BMO Capital analyst Michael Zaremski maintains Selective Insurance Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGI#NASDAQ">SIGI</a>) with a Outperform and raises the price target from $92 to $96.

SIGI

BMO Capital Maintains Outperform on Selective Insurance Gr, Raises Price Target to $96

UBS analyst Taylor McGinnis maintains Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) with a Neutral and lowers the price target from $350 to $310.

MNDY

UBS Maintains Neutral on Monday.Com, Lowers Price Target to $310

BMO Capital analyst Ari Klein maintains SBA Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>) with a Market Perform and raises the price target from $230 to $240.

SBAC

BMO Capital Maintains Market Perform on SBA Communications, Raises Price Target to $240

UBS analyst Pradeep Ramani maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Buy and lowers the price target from $70 to $55.

MCHP

UBS Maintains Buy on Microchip Technology, Lowers Price Target to $55

AZZ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZZ#NYSE">AZZ</a>) has outperformed the market over the past 20 years by 8.88% on an annualized basis producing an average annual return of 16.92%. Currently, AZZ has a market capitalization of $2.57 billion. 
Buying $1000 In AZZ: If an investor had bought $1000 of AZZ stock 20 years ago, it would be worth $22,594.59 today based on a price of $86.00 for AZZ at the time of writing.
<h3>AZZ's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745937911_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today

BMO Capital analyst Andrew Strelzik maintains Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) with a Outperform and raises the price target from $515 to $540.

BMO Capital Maintains Outperform on Domino's Pizza, Raises Price Target to $540

UBS analyst Danielle Antalffy maintains InMode (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMD#NASDAQ">INMD</a>) with a Neutral and lowers the price target from $19 to $16.25.

INMD

UBS Maintains Neutral on InMode, Lowers Price Target to $16.25

BMO Capital analyst James Thalacker maintains CMS Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMS#NYSE">CMS</a>) with a Outperform and raises the price target from $77 to $79.

BMO Capital Maintains Outperform on CMS Energy, Raises Price Target to $79

UBS analyst Timothy Arcuri maintains GLOBALFOUNDRIES (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) with a Neutral and lowers the price target from $45 to $37.

UBS Maintains Neutral on GLOBALFOUNDRIES, Lowers Price Target to $37

Piper Sandler analyst James Fish maintains F5 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) with a Neutral and raises the price target from $262 to $269.

FFIV

Piper Sandler Maintains Neutral on F5, Raises Price Target to $269

UBS analyst Timothy Arcuri maintains Entegris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTG#NASDAQ">ENTG</a>) with a Neutral and lowers the price target from $115 to $90.

ENTG

UBS Maintains Neutral on Entegris, Lowers Price Target to $90

Piper Sandler analyst Matt O'Brien reiterates TransMedics Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) with a Overweight and raises the price target from $90 to $105.

Reiteration

TMDX

Piper Sandler Reiterates Overweight on TransMedics Group, Raises Price Target to $105

UBS analyst Timothy Arcuri maintains ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) with a Buy and lowers the price target from $215 to $165.

UBS Maintains Buy on ARM Holdings, Lowers Price Target to $165

Piper Sandler analyst Matthew Clark maintains Preferred Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFBC#NASDAQ">PFBC</a>) with a Overweight and lowers the price target from $108 to $96.

PFBC

Piper Sandler Maintains Overweight on Preferred Bank, Lowers Price Target to $96

Buybacks

Wells Fargo Board Authorizes $40B Stock Repurchase Program

<a href="https://x.com/JStein_WaPo/status/1917220665821634689" title="https://x.com/JStein_WaPo/status/1917220665821634689">https://x.com/JStein_WaPo/status/1917220665821634689</a>

AMZN

Washington Post Reporter, Jeff Stein, On X Posts "Amazon Spox now saying this was never under consideration for the main Amazon website. Says Amazon Haul has considered listing import price duties on certain products"

Comments

Envoy Medical

Envoy Medical (COCH) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル